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Asthma is an inﬂammatory disease in which proinﬂammatory cytokines have a role in inducing abnormalities of airway smooth
muscle function and in the development of airway hyperresponsiveness. Inﬂammatory cytokines alter calcium (Ca2+)
signaling and contractility of airway smooth muscle, which results in nonspeciﬁc airway hyperresponsiveness to agonists.
In this context, Ca2+ regulatory mechanisms in airway smooth muscle and changes in these regulatory mechanisms encompass
a major component of airway hyperresponsiveness. Although dynamic Ca2+ regulation is complex, phospholipase C/inositol
tris-phosphate (PLC/IP3) and CD38-cyclic ADP-ribose (CD38/cADPR) are two major pathways mediating agonist-induced
Ca2+ regulation in airway smooth muscle. Altered CD38 expression or enhanced cyclic ADP-ribosyl cyclase activity associated
with CD38 contributes to human pathologies such as asthma, neoplasia, and neuroimmune diseases. This review is focused on
investigations on the role of CD38-cyclic ADP-ribose signaling in airway smooth muscle in the context of transcriptional and
posttranscriptional regulation of CD38 expression. The speciﬁc roles of transcription factors NF-kB and AP-1 in the
transcriptional regulation of CD38 expression and of miRNAs miR-140-3p and miR-708 in the posttranscriptional regulation
and the underlying mechanisms of such regulation are discussed.
1. Introduction
Asthma is an inﬂammatory disease in which proinﬂamma-
tory cytokines have a role in inducing abnormalities of
airway smooth muscle (ASM) function and in the devel-
opment of airway hyperresponsiveness (AHR). Airway
smooth muscle obtained from asthmatics is diﬀerent from
smooth muscle obtained from healthy subjects [1]. Inﬂam-
matory cytokines alter calcium (Ca2+) signaling and contrac-
tility of ASM, which results in nonspeciﬁc AHR to agonists
[2–4]. The increased ASM mass and heightened contractile
response of ASM in asthmatic subjects contribute to airway
narrowing during an asthma episode [5]. The molecular
pathogenesis of asthma includes modulation of expression,
activity, or sensitivity of intracellular signaling molecules
and eﬀector targets in ASM cells. Studies of gene expression
in airway biopsies from mild allergic asthmatics reveal
increased expression of contractile proteins and proteins
involved in the regulation of these proteins, leading to fas-
ter velocity of actin ﬁlament propulsion and AHR [6].
Furthermore, ASM cells from asthmatics proliferate at a
higher rate and are resistant to antimitogenic eﬀect of glu-
cocorticoids, secrete chemokines, and attain a hypercontrac-
tile phenotype [7–9]. In this context, Ca2+ regulatory
mechanisms in ASM and changes in these regulatory mech-
anisms encompass a major component of AHR. Although
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dynamic Ca2+ regulation is complex, phospholipase C/inosi-
tol tris-phosphate (PLC/IP3) and CD38-cyclic ADP-ribose
(CD38/cADPR) are two major pathways mediating agonist-
induced Ca2+ regulation in ASM. We will focus our discus-
sion on CD38/cADPR pathway in this review.
The CD38 gene encodes a glycosylated ~45 kDa type II
transmembrane protein whose enzymatic activity generates
cADPR and adenosine diphosphoribose (ADPR) from
NAD+ and nicotinic acid adenine dinucleotide phosphate
(NAADP) from NADP+. The cADPR and NAADP regulate
Ca2+ signaling and contractility in smooth muscle cells [2].
Extracellular ADP-ribosyl cyclase activity of CD38 leads to
generation of cADPR outside the cells that is believed to enter
cells via membrane channels formed by CD38 dimers or
connexin-43 [10, 11]. Interestingly, recent studies have pro-
vided evidence for expression of type III CD38 in human
multiple myeloma cells wherein the catalytic domain of the
molecule is cytoplasmic and amenable to cytosolic regulation
[12]. Furthermore, site-directed mutagenesis of the cationic
amino acid residues in the amino-terminal region of CD38
results in the conversion from a mixture of type II and type
III orientations to predominantly type III. Recombinant
expression of the type III CD38 in a heterologous cell system
led to elevation of intracellular concentrations of cADPR
[13]. Whether type III CD38 is expressed on ASM mem-
branes and its contribution to cADPR-mediated calcium
release needs additional investigation.
Using pharmacological and genetic approaches in
human cells and tissues, and murine models of asthma, we
have demonstrated the contribution of CD38-cADPR to
ASM Ca2+ signaling and contractility. Airway myocytes
from CD38 knockout (CD38KO) mice exhibit attenuated
intracellular Ca2+ ([Ca2+]i) responses to agonists [2] and
methacholine-induced airway responsiveness in the
CD38KO mice is lower than in wild-type (WT) mice. Alter-
ation in CD38 expression and/or modulation of enzyme
activities associated with CD38 result in altered Ca2+ signal-
ing and contractility of ASM. In murine models of asthma,
we demonstrated the role of CD38 in allergen-induced air-
way inﬂammation and AHR. CD38KO mice develop attenu-
ated AHR following allergen, IL-13, or TNF-α challenge
[14–16]. It is important to note that CD38 is also expressed
on immune cells that are important in humoral and cell-
mediated immune response in asthma [17]. Reconstitution
of WT bone marrow in the CD38KO mice partially restores
the WT airway phenotype following allergen sensitization
and challenge [18]. This suggests that CD38+ inﬂammatory
cells that are recruited into the lungs following allergen chal-
lenge are suﬃcient to impart the WT airway phenotype in
the CD38KO mice. These ﬁndings implicate CD38 in the
pathophysiology of asthma. CD38 has been implicated in
other human pathologies including in neuroinﬂammatory
diseases, renal dysfunctions, neoplastic disorders, and viral
infections (respiratory syncytial virus) [19–22].
Inﬂammatory cytokines such as IL-13 and TNF-α, which
are implicated in asthma, augment CD38 expression and
cADPR-mediated Ca2+ release and increase contractility of
ASM. ASM cells obtained from subjects who died from an
episode of asthma or subjects with a history of stable asthma
show signiﬁcantly enhanced expression of CD38 (both tran-
script and protein) to low concentrations of TNF-α com-
pared to expression in cells from nonasthmatics [5]. This is
signiﬁcant since the TNF-α axis does have a role in asthma
that is refractory to current therapy, and TNF-α levels in
bronchoalveolar lavage (BAL) ﬂuid are elevated in patients
with severe asthma [23–26]. These observations collectively
indicate that the capacity for CD38/cADPR signaling in
[Ca2+]i regulation and contractility of ASM is signiﬁcantly
greater in asthmatic ASM cells than in cells derived from
nonasthmatic subjects. This might arise due to altered
CD38 expression and/or modulation of enzyme activities
associated with CD38. Therefore, we have examined the tran-
scriptional and posttranscriptional regulation of expression
of CD38 in human ASM cells obtained from asthmatics
and healthy subjects. Speciﬁcally, the role of several tran-
scription factors and miRNAs in the regulation of CD38
expression was examined in these studies. Of note, the con-
tribution of CD38 to [Ca2+]I regulation and the underlying
mechanisms of such regulation have been addressed in sev-
eral prior publications and will not be considered here. This
review will focus on the role of various transcription factors
and speciﬁc miRNAs in the regulation of CD38 expression
in ASM (Figure 1).
2. CD38 Gene Organization, Polymorphisms,
and Human Diseases
In the human and mouse, the gene encoding CD38
(CD38, human; cd38, mouse) is localized on chromosomes
4 and 5, respectively [27]. The CD38 polypeptide is encoded
by a >80 kbp length gene comprising 8 exons, more than 98%
being represented by intronic sequences. We have cloned the
promoter region of CD38 (Acc. number DQ091293), and
sequence analysis reveals putative NF-κB, AP-1, C/EBPβ,
glucocorticoid response element (GRE), and an estrogen
response motif [28]. Inducible elements are reported in
the 5′ end of intron 1. In addition, intron 1 is reported
to have a DR5 repeat, the retinoid acid response element,
and a ~900 bp CpG island associated with exon 1 and the
5′ end of intron 1 [29]. Binding of Sp1 to the CpG motif
appears to maintain it in an unmethylated state and this
allows for constitutive expression of CD38 in cells. These
response elements and transactivating regulatory sequences
within the CD38 gene allow for transcriptional regulation
by a diverse array of factors and mechanisms [29–31]. In
diﬀerent cell types, CD38 expression is induced by retinoic
acid through the retinoic acid response element located
within intron 1 of the CD38 gene [32]. Single nucleotide
polymorphisms in regulatory or protein coding regions
of CD38 presumably alter CD38 expression. A polymor-
phism in intron 1 of the human CD38 has been described
[27]. The absence or presence of a PvuII site deﬁnes two
alleles, a CD38∗A allele and a CD38∗B allele. Ferrero et
al. have identiﬁed that in the Italian Caucasian population,
the CD38∗B allele appears to be more frequent than the
CD38∗A allele [27]. Okamoto’s group has also described
a mutation in exon 4 of CD38 in some subjects with type
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II diabetes mellitus [33]. CD38 is implicated in the oxyto-
cin signaling pathway, and single nucleotide polymor-
phisms in this gene have been associated with low serum
oxytocin levels in autism spectrum disorder (ASD)
patients [19, 34, 35]. Disruption of oxytocin signaling has
been associated with features of ASD, including impaired
communication and social behavior, based on animal stud-
ies. Whether polymorphisms in the CD38 gene are associ-
ated with asthma in humans remain to be determined. In
this context, a recent report has identiﬁed an individual
with autism and asthma with an inherited maternal dele-
tion of 4p15.32 resulting in a BST1-CD38 fusion transcript
[36]. This is the ﬁrst report that describes rearrangements
involving CD38 or deletions in patients with ASD.
3. Regulation of CD38 Expression in ASM Cells:
Role of Transcriptional Mechanisms and
Signaling Crosstalk
In prior studies, we demonstrated augmented CD38 expres-
sion, ADP-ribosyl cyclase activity, cADPR production, and
[Ca2+]i responses to agonists in human ASM cells by IL-13
and TNF-α [2–4, 15, 16]. Eﬀects of inﬂammatory cytokines
on CD38 expression and cADPR-mediated calcium release
in human ASM cells have been studied by other investigators
[37–41]. These data suggest that CD38 expression is regu-
lated by cytokines in ASM cells (Figure 1). Numerous studies
have unequivocally demonstrated the central role of inﬂam-
matory and Th2 cytokines in asthma [42]. Furthermore,
mice challenged intranasally with IL-13 or TNF-α exhibited
signiﬁcantly greater airway inﬂammation, BAL cytokine
levels, and augmented methacholine-induced changes in
airway resistance. These changes in the airways were signif-
icantly attenuated in the CD38KO mice compared to
responses in the WT mice. These observations strongly
implicate CD38 in the pathophysiology of asthma in the
mouse models and that IL-13 and TNF-α alter ASM func-
tions [43–45] in part via CD38.
Evidence for TNF-α in the pathogenesis of allergic airway
disease comes from the following observations. Human clin-
ical trials with anti-TNF-α-immunomodulators (etanercept)
and anti-TNF-α monoclonal antibodies (inﬂiximab) have
shown that TNF-α has a role in asthma that is refractory to
corticosteroids [42]. TNF-α secretion following allergen chal-
lenge is higher in atopic asthmatics (i.e., asthmatics with
allergy) than in nonatopics (asthmatics with no clearly
deﬁned allergy) [46, 47]. Aerosolized TNF-α to human vol-
unteers causes AHR [48–50]. In vitro tissue studies have
shown that TNF-α treatment increases contractility and
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Figure 1: Regulation of expression and functional role of CD38. Bifunctional enzyme CD38 is expressed on a variety of immune and
mesenchymal cells including on airway smooth muscle cells. In immune cells, CD38 serves as a cell surface marker and contributes to
inﬂammatory response. CD38 via production of cADPR, a calcium elevating second messenger, contributes to smooth muscle contractility
and airway hyperresponsiveness (right half). Regulating CD38 expression, its enzyme activity or cADPR levels in eﬀector cells may lead to
human pathologies. Inﬂammatory cytokines, hormones, and other inﬂammatory mediators regulate CD38 expression via activation of
transcription factors such as NF-κB and AP-1 or via expression of speciﬁc microRNAs (left half). Overall, CD38 expression can be
modulated at transcriptional level as well as posttranscriptionally by microRNAs.
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Ca2+ signaling in ASM cells [15]. The eﬀects of TNF-α in
corticosteroid-resistant asthma may be mediated by direct
eﬀects to alter the dynamics of the Ca2+ response to agonists
and thereby the contractility of the ASM. TNF-α induces
ASM cell synthesis and release of IL-8 and eotaxin, and upre-
gulates the expression of adhesion molecules, receptors for
inﬂammatory mediators, and growth factors [51, 52]. A poly-
morphism in the 5′ untranslated region of the TNF gene (G-
308A), referred to as TNF-308 GG genotype, is associated
with inﬂammatory diseases including asthma [53].
We have also observed that among the cytokines that
are implicated in asthma, TNF-α causes the greatest
induction of CD38 expression in ASM cells [3, 5]. Fur-
thermore, a single intranasal challenge with TNF-α causes
signiﬁcant augmentation of methacholine-induced airway
resistance in the WT but not in the CD38KO mice [15].
Therefore, we examined the regulation of CD38 expression
in airway myocytes obtained from asthmatic and healthy
human subjects in an attempt to identify signaling inter-
mediates involved in this process and to identify potential
therapeutic targets. Other investigators have demonstrated
that CD38 expression is altered by other cytokines such as
type I interferons and lipopolysaccharide (LPS) in many
other cell types including epithelial cells, renal cells, mac-
rophages, and other immune cells [19, 22].
Sequence analysis of a 3 kb putative CD38 promoter
fragment (Gen-Bank accession number DQ091293) cloned
from a human erythropoietic cell line (K562 cells) in our
laboratory revealed binding sites for NF-κB, AP-1, and
glucocorticoid receptor (GR). To determine whether CD38
expression in human ASM cells is regulated by TNF-α and
GRE, we measured the binding of transcription factors and
the GR to their respective putative sites within this promoter
region [28, 54]. Our results demonstrate that TNF-α causes
increased binding to the NF-κB site and to 3 of the 6 putative
AP-1 sites. Site-directed mutagenesis of the AP-1 site that
exhibited very strong binding of nuclear proteins (AP-1 site
4) or the NF-κB site abolished promoter activation induced
by TNF-α. Regulation of the CD38 gene has also been
investigated in human myeloid cells [32]. In these cells,
CD38 expression is induced by retinoic acid through the
retinoic acid response element located within the ﬁrst
intron of the CD38 gene. Response elements for other
transcription factors, including AP-1, have been described
in osteoblasts and osteoclasts [31], and in these cell lines,
TNF-α-induced activation of a CD38 promoter fragment
requires an intact AP-1 site.
Glucocorticoids are widely used in the management of
inﬂammatory airway diseases [55, 56]. The mechanisms of
action of glucocorticoids are complex and involve transcrip-
tion factors, including NF-κB [56, 57]. The glucocorticoid
dexamethasone increased the binding of GR to 3 of the
4 putative GRE sites within the CD38 promoter and abol-
ished promoter activation induced by TNF-α [28, 54].
These results demonstrate that TNF-α regulates CD38 expres-
sion transcriptionally through NF-κB and AP-1 (Figure 1),
and glucocorticoids decrease this expression possibly by bind-
ing to GREs within the CD38 promoter and/or also by
decreased NF-κB- and AP-1-mediated transcription [28, 54].
Interestingly, Tliba et al. demonstrated thatCD38 augmenting
eﬀect of TNF-α in humanASMcells is insensitive to glucocor-
ticoid treatment, and this steroid resistance involves action of
interferon regulatory factor (IGF)-1 and glucocorticoid recep-
tor β (GR-β) isoform [38, 58].
The mechanisms by which mitogen-activated protein
(MAP) kinases mediate changes in gene expression are
complex and involve the interaction of several proteins
and transcription factors. In ASM cells, MAPKs mediate
changes in the proﬁle of gene expression through phos-
phorylation of intracellular proteins including transcription
factors, and TNF-α causes activation of the MAPKs, that is,
p38, JNK, and ERK1/2, resulting in the regulated expression
of a variety of genes involved in excitation-contraction cou-
pling [59–65]. NF-κB mediates the eﬀects of TNF-α in
ASM and other cell types. Repression of transcription of
proinﬂammatory genes by glucocorticoids involves binding
to GREs within the promoter region and through interac-
tion with transcription factors. With respect to interaction
of GR and regulation through AP-1 and NF-κB, evidence
supports direct interaction between the proteins rather
than inhibition of binding of transcription factors to their
respective response elements [66–71]. GR binding to cis-
acting elements and the trans-acting factors that bind these
are essential for a complete glucocorticoid response. The
anti-inﬂammatory eﬀects of glucocorticoids may be distinct
from the eﬀects on gene transcription and may involve the
MAPK pathways. Glucocorticoids can induce the expression
of a dual speciﬁcity phosphatase 1 (DUSP1), also known as
MAPK phosphatase 1 (MKP-1) [60, 61, 72–74]. MKP-1
causes dephosphorylation and inactivation of the activated
MAPKs. Thus, MKP-1 induction is considered as an impor-
tant anti-inﬂammatory action of glucocorticoids. MAPKs
also regulate the stability of mRNAs for several proinﬂamma-
tory cytokines. We have systematically examined the role of
MAP kinases and glucocorticoids in TNF-α-mediated
CD38 expression in human cells. We also examined whether
the diﬀerential induction of CD38 expression in asthmatic
ASM cells can be attributed to diﬀerential activation of
MAP kinases. Exposure to TNF-α caused a rapid phosphor-
ylation of all three MAP kinases. Dexamethasone decreased
TNF-α-induced phosphorylation of the MAP kinases and
increasedMKP-1 expression. These eﬀects of dexamethasone
resulted in signiﬁcant attenuation of CD38 expression.
Furthermore, in cells transfected with MKP-1-speciﬁc small
interfering RNAs, there was signiﬁcant attenuation of
MKP-1 expression and partial reversal of dexamethasone
inhibition of CD38 expression. These ﬁndings indicate that
regulation of CD38 expression in human ASM cells by glu-
cocorticoids involves decreased signaling through MAP
kinases and activation of transcription factors. Glucocorti-
coid eﬀects on inhibition of CD38 expression involve both
transcriptional and posttranscriptional mechanisms, the lat-
ter through alteration of transcript stability. In human ASM
cells, p38 and ERK MAPKs are involved in CD38 transcript
stability, while the JNK MAPK is involved in transcriptional
regulation of CD38 expression. The 3′UTR of CD38 mRNA
contains A/U rich elements and their role in CD38 mRNA
stability remains to be determined.
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Phosphatidylinositol-3 kinase/Akt pathway (PI3 kinase)
is a key component of intracellular signaling pathways acti-
vated by cytokines, growth factors, and glucocorticoids in
ASM cell [75, 76]. Binding of TNF-α to TNFR1 resulting in
the activation of NF-κB and the MAPK signaling pathways
results in induction of CD38 gene [63, 77]. We have exam-
ined the role of PI3 kinases in the regulation of CD38 expres-
sion and function in human ASM cells [78]. Since our
previous studies showed a diﬀerential induction of CD38
expression by TNF-α in ASM cells derived from asthmatic
subjects, we determined whether PI3Ks are involved in this
diﬀerential induction. Cells were treated with pan-PI3K
inhibitors or class I-selective or isoform-selective PI3K inhib-
itors with and without TNF-α. In other studies, we trans-
fected the cells with a catalytically active form of PI3K or
PTEN or nontargeting or p110 isoform-targeting siRNAs
before exposure to TNF-α and measured CD38 expression,
ADP-ribosyl cyclase activity, and activation of Akt, NF-κB,
and AP-1. TNF-α-induced CD38 expression and enzyme
activity and Akt activation were inhibited by a pan-PI3K
inhibitor. P110 expression by transient transfection increased
Akt activation, and basal and TNF-α-induced CD38 expres-
sion, while PTEN expression attenuated Akt activation and
CD38 expression. Silencing of p110α or –δ isoform by siR-
NAs caused a reduction in TNF-α-induced CD38 expres-
sion in asthmatic and nonasthmatic ASM cells to a
comparable magnitude. Furthermore, the PI3K inhibitors
had no signiﬁcant eﬀect on NF-κB or AP-1 activation. These
results indicated that in human ASM cells, regulation of
CD38 expression is mediated through class I PI3K isoforms,
but PI3K signaling may not be involved in the diﬀerential
induction of CD38 in asthmatic ASM cells.
In addition to the mechanisms of regulation of CD38
in ASM described above, there is also evidence for hor-
monal regulation in other smooth muscles. In this context,
we previously reported estrogen regulation of CD38 expres-
sion in myometrium smooth muscle [79–81]. In ovariecto-
mized rats treated with estrogen, there was enhanced
expression of CD38 in the myometrium compared to expres-
sion in control rats. Furthermore, when we compared CD38
expression in the myometrium obtained from preterm versus
term rats, there was signiﬁcantly greater expression in the
term rat myometrium compared to expression in preterm
rat myometrium. CD38 expression in preterm myometrium
was comparable to expression in myometrium obtained
from ovariectomized rats or from ovariectomized rats
treated with both estrogen and progesterone. The aug-
mented CD38 expression in the myometrium of term rats
or ovariectomized rats treated with estrogen was associated
with enhanced ADP-ribosyl cyclase but not cADPR hydro-
lase activity, suggesting a diﬀerential regulation involving
posttranslational modiﬁcation of the protein. However, the
nature of this posttranslational regulation of CD38 enzyme
activities is not currently known. Other hormones that
might be involved in the regulation of ADP-ribosyl activity
include betamethasone and L-thyroxine. Treatment of renal
cells with thyroxine augments ADP-ribosyl cyclase and
cADPR generation and contributes to nephrotoxicity [82].
The role of retinoic acid in modulating CD38 expression
and cADPR levels in many cell types has been investigated
extensively [32, 83]. Betamethasone, another hormone,
administered antenatally in sheep model leads to increased
CD38 expression and contributes to postnatal hypertension
suggesting a potential augmenting eﬀect of CD38 in periph-
eral vascular resistance [84].
4. Posttranscriptional Regulation of CD38
Expression: Role of MicroRNAs (miRNAs)
miRNAs are noncoding ~22 nt RNAs that have a central
role in posttranscriptional regulation of expression of genes
involved in inﬂammation and other cellular functions
[85–89]. miRNAs regulate gene expression by destabilizing
the transcripts or by translational repression [90]. Evidence
has emerged for their role in airway diseases such as asthma,
COPD, and idiopathic pulmonary ﬁbrosis [91, 92]. miR-21
appears to have a role in Th1/Th2 immune responses to
antigen, suggesting a role in the pathogenesis of allergic
asthma. Other investigations have shown that let-7 and
miR-155 regulate IL-13 signaling and miR-133 in RhoA
expression, thus highlighting their potential role in airway
inﬂammation andAHR [85–88].Web-based target prediction
algorithmswere used to determine potentialmiRNA response
elements in the CD38 3′-untranslated region (3′UTR).
Although the target prediction resulted in the identiﬁcation
of several potential miRNA targets in the 3′UTR, quantitative
RT-PCR showed expression of miR-140-3p and miR-708.
Therefore, we chose to examine the contribution of these two
miRNAs to posttranslational regulation of CD38 expression
in human ASM cells. We employed luciferase reporter assays
to determine miR-140-3p and miR-708 binding to the CD38
3′UTR. In human ASM cells transfected with miR-140-3p or
miR-708 mimics, CD38 mRNA expression and ADP-ribosyl
cyclase activity were signiﬁcantly attenuated compared to
expression and enzyme activity in cells transfected with a con-
trol oligonucleotide. Site-directed mutagenesis of the miRNA
binding sites on the CD38 3′UTR reversed the inhibition of
luciferase activity induced by the miRNA mimics. We then
determinedwhether the diﬀerential induction ofCD38 in cells
from asthmatic airways could be attributed to diﬀerential
induction of expression of miRNAs. Exposure to TNF-α
caused a reduction in the expression of miR-140-3p and
miR-708 to a comparable magnitude in cells from asthmatics
and nonasthmatics. Furthermore, stability of the CD38 tran-
script was unaltered by overexpression of the miRNAs. These
ﬁndings suggest that the reduction of CD38 expression may
arise to a large extent from indirect mechanisms and that the
diﬀerential induction of CD38 expression in asthmatic ASM
cells may not be attributed to diﬀerences in miRNA levels fol-
lowing exposure to TNF-α [93, 94] (Figure 1).
Previous studies showed that MAP kinases are involved
in the regulation of CD38 expression in human ASM cells.
Therefore, we examined the activation of the MAPKs follow-
ing transfection of cells with the miRNAs. In cells transfected
with the miR-140-3p mimic, there was decreased TNF-α-
induced activation of p38 MAPK and NF-κB. On the other
hand, miR-708 transfection caused a reduction in JNK
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MAPK activation and Akt activation. Transfection with miR-
708 also resulted in induction of MKP-1 and PTEN, phos-
phatases that are involved in dephosphorylation of MAPKs
and PI3K signaling, respectively [94]. Prior reports have pro-
vided evidence that PTEN expression in certain cancer cells is
regulated by miRNAs [95, 96]. For example, miR-221 and
miR-222 inhibit PTEN expression by binding to the 3′UTR,
while knockdown of these miRNAs increases PTEN expres-
sion. Furthermore, regulation of PTEN expression in these
cancer cells has a direct eﬀect on tumor cell proliferation,
migration, and invasion. There is evidence that the PI3K/
Akt signaling pathway has a major contribution to ASM pro-
liferation in asthmatics [75, 76]. Therefore, we hypothesize
that by regulating the expression of PTEN and thereby the
PI3K/Akt signaling pathway, miR-708 may have a profound
impact on cell proliferation and airway wall remodeling.
These ﬁndings strongly indicate that indirect mechanisms
are involved in the actions of miRNAs in the regulation of
CD38 expression and in the control of airway inﬂammation
and ASM proliferation.
5. Conclusions
This review outlines the transcriptional and posttranscrip-
tional mechanisms of regulation of CD38 expression and
function in ASM. Using the promoter-luciferase transfec-
tion system and site-directed mutagenesis approaches, we
have demonstrated the critical role of NF-κB and AP-1
transcription factors in such regulation. Cytokines and ste-
roid (glucocorticoids, sex steroids) hormones modulate
CD38 expression in ASM. Our studies on CD38 expression
in the myometrium show estrogen regulation and inhibition
of expression by progesterone. Furthermore, during gesta-
tion, CD38 expression in the myometrium is maintained at
a relatively low level until very close to term when the ratio
of estrogen to progesterone is high. An interesting observa-
tion of these studies is that estrogen-mediated augmented
CD38 expression causes a diﬀerential regulation of the cata-
lytic activities of the enzyme, the mechanisms underlying this
being not well deﬁned. In human ASM cells obtained from
fatal asthmatics, TNF-α induces a signiﬁcantly greater induc-
tion of CD38 expression compared to expression in cells
obtained from nonasthmatic subjects. This diﬀerential
induction of CD38 expression suggests that the capacity for
cADPR-mediated calcium regulation is signiﬁcantly greater
in asthmatic airway smooth muscle cells compared to cells
from healthy subjects. In this context, our previous studies
showed that exposure to TNF-α results in signiﬁcantly
greater airway responsiveness to inhaled methacholine in
the WT than in the CD38KO mice. Furthermore, CD38KO
mice fail to develop an asthmatic airway phenotype following
sensitization and challenge with allergen as well as following
intranasal challenge with IL-13, a Th2 cytokine implicated in
the pathogenesis of asthma. Our recent studies showed that
transfer of bone marrow from WT mice to CD38KO mice
partially restores the WT phenotype following allergen sensi-
tization and challenge. These ﬁndings support the concept
that CD38 expressions in airway structural cells and inﬂam-
matory cells recruited into the lungs following allergen
challenge are both critical for the development of an asth-
matic phenotype. The investigations on the posttranscrip-
tional regulation of CD38 expression provide evidence for
two speciﬁc miRNAs in such regulation. The mechanisms
by which miR-140-3p and miR-708 mediate the inhibitory
eﬀect on CD38 expression are diﬀerent. While miR-140-3p
eﬀects on downregulation of CD38 expression in human
ASM cells are mediated via inhibition of p38 MAPK and
NF-κB activation, the eﬀects of miR-708 eﬀects are via inhi-
bition of JNK MAPK and PI3K activation, the latter by
increased expression of PTEN. Dysregulation of expression
of these two miRNAs should have profound eﬀects on
CD38 expression and airway function.
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